These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37016035)

  • 1. Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study.
    Zheng Q; Bao C; Ji Y; Li P; Ma Z; Wang X; Meng Q; Pan Q
    Sci Rep; 2023 Apr; 13(1):5474. PubMed ID: 37016035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic.
    Kikuchi K; Nangaku M; Ryuzaki M; Yamakawa T; Ota Y; Hanafusa N; Sakai K; Kanno Y; Ando R; Shinoda T; Wakino S; Nakamoto H; Takemoto Y; Akizawa T;
    Ther Apher Dial; 2023 Dec; 27(6):1064-1069. PubMed ID: 37395555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
    Bai Y; Shen M; Zhang L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance.
    Flisiak R; Zarębska-Michaluk D; Rogalska M; Kryńska JA; Kowalska J; Dutkiewicz E; Dobrowolska K; Jaroszewicz J; Moniuszko-Malinowska A; Rorat M; Podlasin R; Tronina O; Rzymski P
    Pharmacol Rep; 2022 Dec; 74(6):1279-1285. PubMed ID: 36001284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pandemic COVID-19, an update of current status and new therapeutic strategies.
    Vitiello A; La Porta R; Trama U; Ferrara F; Zovi A; Auti AM; Di Domenico M; Boccellino M
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Oct; 395(10):1159-1165. PubMed ID: 35779085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molnupiravir: an antiviral drug against COVID-19.
    Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
    Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient treatment options to address the SARS-CoV-2 variant Omicron.
    McCarthy MW
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1129-1133. PubMed ID: 35549623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection.
    Metzdorf K; Jacobsen H; Greweling-Pils MC; Hoffmann M; Lüddecke T; Miller F; Melcher L; Kempf AM; Nehlmeier I; Bruder D; Widera M; Ciesek S; Pöhlmann S; Čičin-Šain L
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why Molnupiravir Fails in Hospitalized Patients.
    Brown AN; Lang Y; Zhou J; Franco EJ; Hanrahan KC; Bulitta JB; Drusano GL
    mBio; 2022 Dec; 13(6):e0291622. PubMed ID: 36374076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic.
    Garzi G; Cinetto F; Firinu D; Di Napoli G; Lagnese G; Punziano A; Bez P; Cinicola BL; Costanzo G; Scarpa R; Pulvirenti F; Rattazzi M; Spadaro G; Quinti I; Milito C
    Front Immunol; 2022; 13():947174. PubMed ID: 35967382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic.
    Suzuki Y; Shibata Y; Minemura H; Nikaido T; Tanino Y; Fukuhara A; Kanno R; Saito H; Suzuki S; Inokoshi Y; Sando E; Sakuma H; Kobayashi T; Kume H; Kamimoto M; Aoki H; Takama A; Iizuka T; Kamiyama T; Nakayama M; Saito K; Tanigawa K; Sato M; Waragai Y; Kambe T; Kanzaki N; Azuma T; Okamoto H; Sakamoto K; Nakamura Y; Ohtani H; Waragai M; Maeda S; Ishida T; Sugino K; Abe W; Tsukada Y; Lee T; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Watanabe N; Rikimaru M; Kawamata T; Morimoto J; Togawa R; Sato Y; Saito J; Kanazawa K; Hamaguchi S; Iseki K
    Clin Exp Med; 2023 Oct; 23(6):2715-2723. PubMed ID: 36469171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the Omicron variant development.
    Vitiello A; Ferrara F; Auti AM; Di Domenico M; Boccellino M
    J Intern Med; 2022 Jul; 292(1):81-90. PubMed ID: 35289434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real life experience of molnupiravir as a treatment of SARS-CoV-2 infection in vaccinated and unvaccinated patients: a letter on its effectiveness at preventing hospitalization.
    Scioscia G; De Pace CC; Giganti G; Tondo P; Foschino Barbaro MP; Lacedonia D
    Ir J Med Sci; 2023 Oct; 192(5):2301-2303. PubMed ID: 36454535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.
    Khiali S; Khani E; B Rouy S; Entezari-Maleki T
    Future Microbiol; 2022 Mar; 17(5):377-391. PubMed ID: 35199608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of the Swiss Digital Contact-Tracing App Over Various SARS-CoV-2 Pandemic Waves: Repeated Cross-sectional Analyses.
    Daniore P; Nittas V; Ballouz T; Menges D; Moser A; Höglinger M; Villiger P; Schmitz-Grosz K; Von Wyl V
    JMIR Public Health Surveill; 2022 Nov; 8(11):e41004. PubMed ID: 36219833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial.
    Zou R; Peng L; Shu D; Zhao L; Lan J; Tan G; Peng J; Yang X; Liu M; Zhang C; Yuan J; Wang H; Li S; Lu H; Zhong W; Liu Y
    Front Pharmacol; 2022; 13():939573. PubMed ID: 35784723
    [No Abstract]   [Full Text] [Related]  

  • 20. Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
    Mazzotta V; Cozzi Lepri A; Colavita F; Rosati S; Lalle E; Cimaglia C; Paulicelli J; Mastrorosa I; Vita S; Fabeni L; Vergori A; Maffongelli G; Carletti F; Lanini S; Caraffa E; Milozzi E; Libertone R; Piselli P; Girardi E; Garbuglia A; Vaia F; Maggi F; Nicastri E; Antinori A;
    J Med Virol; 2023 Jan; 95(1):e28186. PubMed ID: 36184918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.